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European Federation of Pharmaceutical Industries and Associa-
tions (EFPIA) and Pharmaceutical Research and Manufacturers
of America (PhRMA).
Results In total, 323 clinical trial sponsors were listed in Trial-
sTracker, of which 69 were pharmaceutical industry sponsors
and 31 were ranked in the top 50 pharmaceutical companies.
Of these, 25/31 were EFPIA/PhRMA members and 6/31 were
non-members. The disclosure rate for each year from 2006 to
2015 was 42.9%, 54.4%, 81.0%, 86.1%, 84.6%, 87.2%,
89.3%, 82.1%, 84.1% and 73.4%; reporting of clinical trial
results became mandatory in 2008. The disclosure rate (dis-
closed trials/eligible trials) between 2006 and 2015 was greater
for all pharmaceutical industry sponsors (7037/9511 [74.0%])
than for non-industry sponsors (9074/19866 [45.7%])
(p<0.01). For the top 50 companies, results were disclosed
for 4761/6235 trials (76.4%) between 2006 and 2015, with
similar disclosure rates for EFPIA/PhRMA members (4336/
5697 [76.1%]) and non-members (425/538 [79.0%]).
Conclusions According to TrialsTracker, the pharmaceutical
industry has disclosed the results of three quarters of trials
completed between 2006 and 2015. The disclosure rate for
pharmaceutical industry sponsors is greater than for non-indus-
try sponsors. Because TrialsTracker excludes sources other than
ClinicalTrials.gov (e.g. company websites), this figure may be
an underestimate.
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Objectives Competing interests among patient decision aid
developers have the potential to undermine the capacity of
these tools to support patients and others to make informed
health decisions. Prominent decision aid quality frameworks
(e.g., the International Patient Decision Aids Standards
(IPDAS), the (United States) National Standards for the Certif-
ication of Patient Decision Aids) attempt to address this issue
by advocating disclosure of decision aid funding sources and
developers’ competing interests. Although the adequacy of this
approach has been questioned on more than one occasion, we
are aware of no empirical evidence pertaining to patients’
understanding of and reactions to competing interest disclo-
sure statements. Here we present a secondary analysis of data
collected in the process of developing a patient decision aid
on postpartum contraception to shed light on this issue.
Method We administered an online survey of people who
were currently pregnant and/or £24 months postpartum, could
read and write English, and resided in the United States. Par-
ticipants were recruited using a commercial panel service. As
part of the survey, we presented participants with a list of six
information elements and solicited their views on whether
each ought to be included in the decision aid itself or in a
supporting document. One of the information elements was,
‘information about whether those who wrote the guide will
make money based on what decisions people make after using
the guide’. Other elements pertained to decision aid
development and user testing, evidence sources, update policy,
readability, and authors and their qualifications. Immediately
after this, an open text question invited participants to elabo-
rate on their responses or make additional suggestions.
Results Of the 286 eligible participants, 46% responded that
information on competing interests should be included in the
decision aid itself, while 54% felt that it should be included
in a supporting document. Notably, competing interest infor-
mation was endorsed for inclusion in the decision aid less fre-
quently than most other information elements. Some
participants’ open text responses reiterated the perceived
importance of competing interest information (‘Full disclosure
of who is to profit from choices presented by the guide.’)
However, other participants’ comments suggested a limited
understanding of its relevance and/or little interest in it (‘I
don’t think people need information about what is going to
happen with money when using the guide, it has nothing to
do with birth control,’ ‘The information is more important
than who is making money off it because someone is always
making money off something’).
Conclusions Relying on mere disclosure of competing interests
among patient decision aid developers may not adequately
mitigate the negative effects of those interests for all decision
aid users. Further research dedicated to exploring diverse
patients’ understanding of and attitudes toward competing
interest disclosure statements, as well as if and how such
statements modify patients’ interpretation of the content and
perceived trustworthiness of the decision aid, is warranted.
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Objectives Using data to improve care and outcomes is partic-
ularly important for developing countries with high burden of
disease and inferior health outcomes. However, there is lim-
ited use of data in resource-limited settings based on evidence.
The aim of this work is to highlight the significant role of
data to improve care and outcomes in resource-limited settings
and outline the barriers and potential solutions to use data
for evidence-based decision-making in developing countries.
The study also aims to reflect on a practical example of using
real-world data at the Children’s Cancer Hospital 57357 –
Egypt (CCHE) and proposes the use of predictive analytics/
modelling to improve care delivery and outcomes for children
with cancer in Egypt through building learning health systems.
Method We reviewed the literature on the use of health data
and analytics to improve care and health outcomes in
resource-limited settings, to determine available applications,
barriers and potential solutions for implementation in develop-
ing countries. We searched on PubMed, Google, and Google
Scholar using search terms ‘health data’, ‘data-driven improve-
ments’, ‘big data’, ‘advanced analytic’, ‘resource-limited set-
tings’, ‘developing countries’, ‘improving outcomes’, ‘barriers’,
‘potential solutions’, and ‘EMR’. This was followed by reflec-
tion on a practical example of using real world data to
improve care delivery and outcomes at CCHE and a proposed
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Conclusions This study provides an overview of different
methods used to and/or reported on identifying gaps, deter-
mining research priorities and displaying both gaps and
research priorities. These study findings can be adapted to
inform the development of methodological guidance on ways
to advance methods to identify, prioritise and display gaps to
inform research and evidence-based decision-making.
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Objectives Qualitative and quantitative data relevant to rando-
mised controlled trials (RCT), manually extracted and analysed
within Cochrane reviews, are available to those who have
access to the Cochrane Library. If, however, one wished to re-
use these data, all information has to be extracted from that
review before that process can start. There are great benefits
of widely sharing data – and drawbacks in not sharing. This
work explores whether it is possible to i. extract all trial data
from the systematic reviews; and prepare these data to be
widely accessed. Therefore, the aim is to make the process of
transposing data from RCTs into a web-based curated, accessi-
ble database easy.
Method Resources for this work are 200 systematic reviews of
the Cochrane Schizophrenia Group (Nottingham) and open
source software.
We produced a Java-based app with functionality to extract
all trial data from a list of systematic reviews. (The reviews,
available in ReviewManager5 format, are parsed as the app
accesses relevant parts of the reviews; in turn the data within
the included studies are parsed into a format that can be
downloaded, uploaded and reused).
This creates the possibility for results to be stored in a way
that:
. all relevant data are ready to be used by others
. data can be auto–tidied and re–planted back into the source
review
Results The product of this work is a simple end-user app. By
its use Cochrane groups can create a database with all data
they have extracted for their reviews.
Conclusions Supporting auto-extraction, auto-curation, wide
dissemination and re-use of well-extracted data has advantages
for all. There are many imaginative things that can be done
with these data for all categories of end-users.
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Objectives
Introduction Using a study-based register in the process of sys-
tematic reviewing reduces waste and makes it possible to
shortcut many processes normally undertaken by review teams.
However, this works for simple ‘Intervention X vs Interven-
tion Y for Condition Z’-style reviews, but the challenge is to
provide the same shortcuts for systematic reviews of classes of
interventions, overviews or network meta-analyses. As one
might expect an Information Specialist to say, classification is
the answer.
Objectives To report experience and progress with specific
classification of healthcare conditions, interventions, and out-
comes for the purposes of facilitating systematic reviews.
Methods We used the study-based Register of Cochrane Schiz-
ophrenia Group (in MS-Access MeerKat 1.6; holds 25 212
reports of 18 105 studies – 28 Feb 2018). The PICO meta-
data (health care problems, interventions, comparisons, and
outcomes) of each study have been extracted. We used NLM’s
MeSH, The British National Formulary, and WHO ATC clas-
sification system.
Results Health care problems: In the 18 105 studies we identi-
fied 266 health care problems within schizophrenia trials
which were specific focus of the evaluation – amongst which
negative symptoms (546 trials), treatment resistance (467 tri-
als), depression (350 trials), tardive dyskinesia (293 trials) and
weight gain (260 trials) were the most common.
Interventions: Of the 3910 interventions randomised within
these trials, we found 155 classes of drugs with antipsychotics,
antidepressants, and benzodiazepines being the most
researched. There are 41 additional specific interventions
related to some sort of physical/exercise approach. Classifying
psychological interventions, and Chinese Traditional Medicine
(with its 537 trials with 246 interventions) remains a
challenge.
Outcomes: We use seven main classes for outcomes within
schizophrenia reviews: Global State, Mental State, Adverse
Events, Functioning, Service Use, Quality of Life, and Cost.
We propose to use existing classification of outcome tools to
clean and curate the 13 187 outcomes. Classification heaven!
Conclusions Better reporting of PICO meta-data would help
and improve classification. However, all current classification
systems do not really fit the systematic review purpose. New
systems, designed with systematic review output in mind,
greatly enhance the review process (including prioritisation of
titles) and reviewer experience (including prioritisation of
effort).
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Objectives To evaluate disclosure of clinical trials registered by
pharmaceutical companies using an independent, semi-auto-
mated tool (TrialsTracker; https://trialstracker.ebmdatalab.net/#/
).
Method For the top 50 pharmaceutical companies (2014
global sales; EvaluatePharma, London, UK), registered inter-
ventional phase 2–4 clinical trials completed in 2006–2015
were identified in TrialsTracker, which calculates annual disclo-
sure rates for sponsors of over 30 studies registered on Clini-
calTrials.gov. The proportion of trials with results disclosed by
April 2017 was analysed by company membership of the
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